Prescription ·Strong evidence ·Reviewed May 2026
Methylprednisolone is a synthetic glucocorticoid available in oral, intramuscular, intravenous, and intra-articular formulations. IV methylprednisolone (Solu-Medrol) is frequently used for acute flares of multiple sclerosis, severe asthma, transplant rejection, and other inflammatory emergencies. The oral form (Medrol) is commonly dispensed as a dose pack for short-term anti-inflammatory therapy.
The bottom line
Evidence rating strong. Most-documented uses: potent anti-inflammatory and immunosuppressive activity, multiple formulations for flexible clinical use, iv pulse therapy for acute inflammatory crises. 10 sources indexed (2017–2024), with 7 interaction records on file.
Core mechanism
Binds intracellular glucocorticoid receptors, forming a complex that translocates to the nucleus and modulates transcription of inflammatory genes. Inhibits phospholipase A2 (via lipocortin induction), reducing prostaglandin and leukotriene synthesis. Suppresses NF-kB-mediated transcription of pro-inflammatory cytokines. Also reduces vascular permeability, stabilizes lysosomal membranes, and decreases immune cell activation and migration.3,7
Oral tablets should be taken with food. IV form given as slow infusion. Intra-articular injections should not be repeated more than every 3 months in the same joint.
Nutrients this medication can lower over time, and what to replace.
Glucocorticoids reduce intestinal calcium absorption, increase urinary calcium loss, and accelerate bone resorption.
Glucocorticoids impair activation and signaling of vitamin D, reducing calcium absorption and bone support.
Systemic corticosteroids can promote potassium loss or shifts in susceptible patients, especially at higher doses or with other hypokalemia risks; replacement should be lab-guided.
Chronic corticosteroid use can increase urinary magnesium losses and worsen low magnesium status.
Like all glucocorticoids, methylprednisolone reduces calcium absorption and increases bone loss. Calcium supplementation is recommended for patients on chronic corticosteroid therapy.
Recommendation: Supplement 1000-1200mg calcium daily during chronic methylprednisolone therapy, combined with vitamin D3.
Methylprednisolone accelerates vitamin D catabolism. Vitamin D supplementation is standard care for glucocorticoid-induced osteoporosis prevention.
Recommendation: Supplement 1000-2000 IU D3 daily. Monitor 25(OH)D levels.
Chronic methylprednisolone exposure can reduce bone density and raise fracture risk. Vitamin D2 can help maintain vitamin D status and calcium absorption, which are core parts of glucocorticoid-induced osteoporosis prevention.
Recommendation: If methylprednisolone is used beyond a short course, maintain vitamin D status and ask whether bone density testing or prescription osteoporosis prevention is appropriate. Vitamin D2 should complement calcium intake and risk-based treatment decisions, not replace them.
Methylprednisolone can cause bone loss when used repeatedly or chronically. Strontium supplements can raise apparent DXA bone density independent of true bone strength, complicating monitoring for glucocorticoid-induced osteoporosis.
Recommendation: If you use strontium while taking methylprednisolone, make sure it is recorded before DXA testing and osteoporosis decisions. Do not use strontium to self-treat steroid-induced bone loss without clinician guidance.
High-dose or pulse methylprednisolone can disturb potassium handling and has been associated with clinically relevant rhythm concerns in vulnerable patients. Potassium supplementation can correct confirmed hypokalemia, but it should be guided by lab results.
Recommendation: Have potassium monitored during high-dose, IV pulse, or prolonged methylprednisolone therapy, especially if you have kidney disease, heart disease, or take diuretics. Do not self-treat with high-dose potassium unless your potassium level and kidney function are known.
Schisandra extract has human evidence of inhibiting CYP3A activity, and methylprednisolone exposure is highly sensitive to CYP3A inhibition. Combining them could raise steroid exposure and increase systemic adverse effects such as mood changes, high glucose, fluid retention, and adrenal suppression.
Recommendation: Avoid starting high-dose Schisandra during methylprednisolone therapy unless your prescriber knows. If the combination is used, monitor for stronger steroid effects and do not abruptly stop methylprednisolone after prolonged use.
St. John's Wort products high in hyperforin induce CYP3A, and methylprednisolone is a CYP3A-sensitive steroid. This may lower methylprednisolone exposure and reduce anti-inflammatory or immunosuppressive effect, especially when steroid treatment is being used for an active flare or severe inflammation.
Recommendation: Avoid starting St. John's Wort during methylprednisolone therapy unless your prescriber approves. If you already take it, do not stop or start it abruptly without discussing steroid response and possible dose implications.
Numbered references. Citations throughout the page link here.
Mehmood F, Rizvi SAR, Alam S et al.. Teprotumumab versus intravenous methylprednisolone in thyroid eye disease: A systematic review. Oman journal of ophthalmology. 2024
Xu W, Zeng Y, Han H et al.. The role of methylprednisolone in severe COVID-19 patients: a meta-analysis. Frontiers in medicine. 2024
Hong S, Wang H, Li S et al.. A systematic review and meta-analysis of glucocorticoids treatment in severe COVID-19: methylprednisolone versus dexamethasone. BMC infectious diseases. 2023
Hong S, Wang H, Zhang Z et al.. The roles of methylprednisolone treatment in patients with COVID-19: A systematic review and meta-analysis. Steroids. 2022
Zhang Y, Gao YL, Zhang LH. Methylprednisolone and local anesthetic for long-term postherpetic neuralgia: a meta-analysis. The Journal of dermatological treatment. 2022
Fehlings MG, Wilson JR, Harrop JS et al.. Efficacy and Safety of Methylprednisolone Sodium Succinate in Acute Spinal Cord Injury: A Systematic Review. Global spine journal. 2017
This page is educational. Do not start, stop, or change a supplement or medication based on it without checking with a qualified healthcare professional.
Use this with your stack
Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.
NutriStack is an informational and organizational tool, not a medical service, and not a substitute for professional advice. Always consult a qualified healthcare professional before starting, stopping, or changing any supplement or medication.
NutriStack